Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 410

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B

Open access
Villeneuve, Jean-Pierre, Condreay, Lynn D., Willems, Bernard, Pomier-Layrargues, Gilles, Fenyves, Daphna, Bilodeau, Marc, Leduc, Raymond, Peltekian, Kevork, Wong, Florence, Margulies, Mariana, Heathcote, Jenny E.·2000·Hepatology

Abstract

The prognosis of decompensated cirrhosis resulting from chronic hepatitis B is poor, and the benefits of treatment with interferon are outweighed by serious side effects and by the risk of fatal exacerbation of disease activity. Lamivudine rapidly reduces hepatitis B virus (HBV)-DNA in serum to undetectable levels. We have treated 35 patients with chronic hepatitis B and decompensated cirrhosis with lamivudine 100 mg or 150 mg orally once daily. Pretreatment, all were positive for HBV-DNA in serum. Ten had Child-Pugh class B and 25 had Child-Pugh class C liver disease. Seven patients underwent liver transplantation within 6 months of treatment initiation, 5 patients died within 6 months, and 23 patients were treated for at least 6 months (mean = 19 months). In a majority of these 23 cases, there was a slow but marked improvement in liver function, which was most apparent after 9 months of treatment, with a decrease in serum bilirubin from 67 ± 13 to 30 ± 4 μmol/L (P< .05, baseline vs. 9 months), an increase in serum albumin from 27 ± 1 to 34 ± 1g/L (P< .05), and a decrease in Child-Pugh score from 10.3 ± 0.4 to 7.5 ± 0.5(P< .05). Three patients developed resistance to lamivudine because of a mutation in the YMDD motif, but liver function did not deteriorate. We conclude that inhibition of viral replication with lamivudine results in a significant improvement of liver function in patients with decompensated HBV cirrhosis, but the long-term benefits remain uncertain.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.510310130

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 410

Metadata

Authors
Villeneuve, J.-P., Condreay, L. D., Willems, B., Pomier-Layrargues, G., Fenyves, D., Bilodeau, M., Leduc, R., Peltekian, K., Wong, F., Margulies, M., & Heathcote, J. E.
Venue
Hepatology
Published
2000-01
Volume
31
Issue
1
Pages
207-210
ISSN
0270-9139 (ISSN-L)
OpenAlex
W2049604384
Cited by
410
References
5
FWCI
28.08
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. https://app.cochat.ai/papers/10.1002/hep.510310130
The paper
Villeneuve, J.-P., Condreay, L. D., Willems, B., Pomier-Layrargues, G., Fenyves, D., Bilodeau, M., Leduc, R., Peltekian, K., Wong, F., Margulies, M., & Heathcote, J. E. (2000). Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology. https://doi.org/10.1002/hep.510310130

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.